Solid Biosciences (NASDAQ: SLDB) grants director 77,500 stock options

Rhea-AI Filing Summary

Solid Biosciences Inc. director Adam Leo Stone received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no cost as a compensation grant.

The option grant vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the company’s next annual stockholder meeting after that date. Any unvested portion will vest automatically upon specified change in control events, and the options expire on June 10, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stone Adam Leo

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 77,500 options Exercise price: $6.61 per share Expiration date: June 10, 2036 +1 more

4 metrics

Option grant size 77,500 options Director stock option grant on June 10, 2026

Exercise price $6.61 per share Exercise price for director stock options

Expiration date June 10, 2036 Option expiration for director grant

Shares underlying options 77,500 shares Common stock underlying the director options

Key Terms

Director Stock Option (Right to Buy), exercise price, expiration date, change in control events

4 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 6.6100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

change in control events financial

"will vest automatically as to 100% of the unvested portion of such option upon specified change in control events"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stone Adam Leo

(Last) (First) (Middle)

C/O PERCEPTIVE ADVISORS LLC

51 ASTOR PLACE, 10TH FLOOR

(Street)

NEW YORK NEW YORK 10003

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	Adam Leo Stone	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Solid Biosciences (SLDB) report in this Form 4 filing?

Solid Biosciences reported a compensation-related stock option grant to director Adam Leo Stone. He received options for 77,500 shares of common stock at a $6.61 exercise price, vesting over time and expiring in 2036, with no open-market stock purchase or sale involved.

How many Solid Biosciences (SLDB) options were granted to the director?

Adam Leo Stone was granted stock options on 77,500 underlying shares of Solid Biosciences common stock. This entire amount represents a new award, bringing his total options reported in this filing to 77,500 shares following the transaction, all held directly as a director compensation grant.

What is the exercise price and term of the SLDB director stock options?

The director stock options have a $6.61 per share exercise price and expire on June 10, 2036. They were granted at no cost to the director and may be exercised for common shares once vested, subject to the specified vesting conditions and expiration date.

How do the Solid Biosciences (SLDB) options granted to the director vest?

The options vest in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the next annual meeting of stockholders after that date. Any unvested portion also fully vests automatically upon specified change in control events affecting the company.

Is this SLDB Form 4 a market purchase or sale of shares?

No, this Form 4 reflects a grant of director stock options, not a market trade. The award is compensation with a $6.61 exercise price, covering 77,500 underlying shares, and there are no reported open-market purchases or sales of Solid Biosciences common stock in this filing.

How many Solid Biosciences (SLDB) derivative securities does the director hold after this grant?

Following this grant, Adam Leo Stone holds 77,500 director stock options as reported in the filing. These options relate to an equal number of underlying common shares and represent his position from this award, which will become exercisable as the vesting conditions are satisfied over time.